Time-dependent changes in hepatic and intestinal induction of cytochrome P450 3A after administration of dexamethasone to rats

References

• Abdel-Razzak Z, Loyer P, Fautrel A, et al. (1993). Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44:707–15
   PubMed Web of Science ®Google Scholar
• Abuasal BS, Bolger MB, Walker DK, Kaddoumi A. (2012). In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. Mol Pharm 9:492–504
   PubMed Web of Science ®Google Scholar
• Aungst BJ. (1993). Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 82:979–87
   PubMed Web of Science ®Google Scholar
• Ayed-Boussema I, Pascussi JM, Maurel P, et al. (2012). Effect of aflatoxin B1 on nuclear receptors PXR, CAR, and AhR and their target cytochromes P450 mRNA expression in primary cultures of human hepatocytes. Int J Toxicol 31:86–93
   PubMed Web of Science ®Google Scholar
• Bailey I, Gibson GG, Plant K, et al. (2011). A PXR-mediated negative feedback loop attenuates the expression of CYP3A in response to the PXR agonist pregnenalone-16α-carbonitrile. PLoS One [Online]. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0016703 [last accessed 18 Sep 2012
   Web of Science ®Google Scholar
• Bressler R. (2006). Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics 61:12–8
   PubMed Web of Science ®Google Scholar
• Burk O, Koch I, Raucy J, et al. (2004). The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 279:38379–85
   PubMed Web of Science ®Google Scholar
• Cheng X, Klaassen CD. (2008). Perfluorocarboxylic acids induce cytochrome P450 enzymes in mouse liver through activation of PPAR-alpha and CAR transcription factors. Toxicol Sci 106:29–36
   PubMed Web of Science ®Google Scholar
• Cotreau MM, von Moltke LL, Beinfeld MC, Greenblatt DJ. (2000). Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. J Pharmacol Toxicol Methods 43:41–54
   PubMed Web of Science ®Google Scholar
• de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. (1999). Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37:485–505
   PubMed Web of Science ®Google Scholar
• Dickmann LJ, Patel SK, Wienkers LC, Slatter JG. (2012). Effects of interleukin 1β (IL-1β) and IL-1β/Interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Curr Drug Metab 13:930–7
   PubMed Web of Science ®Google Scholar
• Eeckhoudt SL, Horsmans Y, Verbeeck RK. (2002). Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 32:975–84
   PubMed Web of Science ®Google Scholar
• Emoto C, Yamato Y, Sato Y, et al. (2008). Non-invasive method to detect induction of CYP3A4 in chimeric mice with a humanized liver. Xenobiotica 38:239–48
   PubMed Web of Science ®Google Scholar
• Floren LC, Bekersky I, Benet LZ, et al. (1997). Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62:41–9
   PubMed Web of Science ®Google Scholar
• Gödtel-Armbrust U, Metzger A, Kroll U, et al. (2007). Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John’s wort. Naunyn-Schmiedebergs Arch Pharmacol 375:377–82
   PubMed Web of Science ®Google Scholar
• Guillén MI, Donato MT, Jover R, et al. (1998). Oncostatin M down-regulates basal and induced cytochrome P450 in human hepatocytes. J Pharmacol Exp Ther 285:127–34
   PubMed Web of Science ®Google Scholar
• Hatorp V, Hansen KT, Thomsen MS. (2003). Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 43:649–60
   PubMed Web of Science ®Google Scholar
• Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. (1992). Bioavailability of cyclosporine with concomitant Rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453–7
   PubMed Web of Science ®Google Scholar
• Ho Y-F, Huang D-K, Hsueh W-C, et al. (2009). Effects of St. John’s wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts. Life Sci 85:296–302
   PubMed Web of Science ®Google Scholar
• Jurica J, Dostálek M, Konecný J, et al. (2007). HPLC determination of midazolam and its three hydroxy metabolites in perfusion medium and plasma from rats. J Chromatogr B Analyt Technol Biomed life Sci 852:571–7
   PubMed Web of Science ®Google Scholar
• Kanazu T, Okamura N, Yamaguchi Y, et al. (2005). Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A4 drug-drug interaction model rats. Xenobiotica 35:305–17
   PubMed Web of Science ®Google Scholar
• Lee CM, Pohl J, Morgan ET. (2009). Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocytes cultures. Drug Metab Dispos 37:865–72
   PubMed Web of Science ®Google Scholar
• Lin YS, Lockwood GF, Graham MA, et al. (2001). In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11:781–91
   PubMedGoogle Scholar
• Lin YH, Peng FC. (2008). Predicting the contribution of rat cytochrome P-450 3A1, 3A2 and human cytochrome P-450 3A4, 3A5 to territrem a 4beta-C hydroxylation using the relative activity factor. J Toxicol Environ Health A 71:1407–14
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193:265–75
   PubMed Web of Science ®Google Scholar
• Luo G, Guenthner T, Gan LS, Humphreys WG. (2004). CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 5:483–505
   PubMed Web of Science ®Google Scholar
• Martin P, Riley R, Back DJ, Owen A. (2008). Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br J Pharmacol 153:805–19
   PubMed Web of Science ®Google Scholar
• Medina-Díaz IM, Estrada-Muñiz E, Reyes-Hernández OD, et al. (2009). Arsenite and its metabolites, MMA(III) and DMA(III), modify CYP3A4, PXR and RXR alpha expression in the small intestine of CYP3A4 transgenic mice. Toxicol Appl Pharmacol 239:162–8
   PubMed Web of Science ®Google Scholar
• Meredith C, Scott MP, Renwick AB, et al. (2003). Studies on the induction of rat hepatic CYP1A, CYP2B, CYP3A and CYP4A subfamily form mRNAs in vivo and in vitro using precision-cut rat liver slices. Xenobiotica 33:511–27
   PubMed Web of Science ®Google Scholar
• Minocha M, Mandava NK, Kwatra D, et al. (2011). Effect of short term and chronic administration of Sutherlandia frutescens on pharmacokinetics of nevirapine in rats. Int J Pharm 413:44–50
   PubMed Web of Science ®Google Scholar
• Mnif W, Pascussi JM, Pillon A, et al. (2007). Estrogens and antiestrogens activate hPXR. Toxicol Lett 170:19–29
   PubMed Web of Science ®Google Scholar
• Nieminen TH, Hagelberg NM, Saari TI, et al. (2009). Rifampin greatly reduces the plasma concentration of intravenous and oral oxycodone. Anesthesiology 110:1371–8
   PubMed Web of Science ®Google Scholar
• Nishimura M, Yokoi T, Tateno C, et al. (2005). Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 20:121–6
   PubMedGoogle Scholar
• Oh WS, Kim DN, Jung J, et al. (2008). New combined model for the prediction of regioselectivity in cytochrome P450/3A4 mediated metabolism. J Chem Inf Model 48:591–601
   PubMed Web of Science ®Google Scholar
• Oscarson M, Zanger UM, Rifki OF, et al. (2006). Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther 80:440–56
   PubMed Web of Science ®Google Scholar
• Paine MF, Shen DD, Kunze KL, et al. (1996). First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14–24
   PubMed Web of Science ®Google Scholar
• Park H, Lee S, Suh J. (2005). Structural and dynamical basis of broad substrate specificity, catalytic mechanism, and inhibition of cytochrome P450 3A4. J Am Chem Soc 127:13634–42
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Fabre JM, et al. (2000). Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: consequences on cytochrome P450 gene regulation. Mol Pharmacol 58:1441–50
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M, Hakkola J, et al. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667–715
   PubMed Web of Science ®Google Scholar
• Pinto AG, Horlander J, Chalasani N, et al. (2005). Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol 59:440–6
   PubMed Web of Science ®Google Scholar
• Riegelman S, Collier P. (1980). The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 8:509–34
   PubMedGoogle Scholar
• Robertoson GR, Field J, Goodwin B, et al. (2003). Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol 64:42–50
   PubMed Web of Science ®Google Scholar
• Roberts AG, Yang J, Halpert JR, et al. (2011). The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4. Biochemistry 50:10804–18
   PubMed Web of Science ®Google Scholar
• Rushmore TH, Kong AN. (2002). Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3:481–90
   PubMed Web of Science ®Google Scholar
• Shimada T, Terada A, Yokogawa K, et al. (2002). Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 74:1419–24
   PubMed Web of Science ®Google Scholar
• Song X, Xie M, Zhang H, et al. (2004). The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes. Drug Metab Dispos 32:35–42
   PubMed Web of Science ®Google Scholar
• Tinel M, Elkahwaji J, Robin MA, et al. (1999). Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J Pharmacol Exp Ther 289:649–55
   PubMed Web of Science ®Google Scholar
• Tomlinson ES, Lewis DF, Maggs JL, et al. (1997). In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem Pharmacol 54:605–11
   PubMed Web of Science ®Google Scholar
• Ueng Y-F, Kuwabara T, Chun Y-J, Guengerich FP. (1997). Cooperatively in oxydations catalyzed by Cytochrome P450 3A4. Biochemistry 36:370–81
   PubMed Web of Science ®Google Scholar
• Ueng Y-F, Tsai C-C, Lo W-S, Yun C-H. (2010). Induction of hepatic cytochrome P450s by the herbal medicine Sophora flavescens extract in rats: impact on the elimination of theophylline. Drug Metab Pharmacokinet 25:560–7
   PubMed Web of Science ®Google Scholar
• Wei P, Zhang J, Dowhan DH, et al. (2002). Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotics response. Pharmacogenomics J 2:117–26
   PubMedGoogle Scholar
• Yokogawa K, Shimada T, Higashi Y, et al. (2002). Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Biochem Pharmacol 63:777–83
   PubMed Web of Science ®Google Scholar